首页> 外文期刊>Journal of the American Chemical Society >Recifin A, Initial Example of the Tyr-Lock Peptide Structural Family, Is a Selective Allosteric Inhibitor of Tyrosyl-DNA Phosphodiesterase 1
【24h】

Recifin A, Initial Example of the Tyr-Lock Peptide Structural Family, Is a Selective Allosteric Inhibitor of Tyrosyl-DNA Phosphodiesterase 1

机译:Tyr-Lock肽结构家族的recifin A,最初的例子是酪氨酸-DNA磷酸二酯酶1的选择性变构抑制剂

获取原文
获取原文并翻译 | 示例
           

摘要

Tyrosyl-DNA phosphodiesterase 1 (TDP1) is a molecular target for the sensitization of cancer cells to the FDA-approved topoisomerase inhibitors topotecan and irinotecan. High-throughput screening of natural product extract and fraction libraries for inhibitors of TDPl activity resulted in the discovery of a new class of knotted cyclic peptides from the marine sponge Axinella sp. Bioassay-guided fractionation of the source extract resulted in the isolation of the active component which was determined to be an unprecedented 42-residue cysteine-rich peptide named recifin A. The native NMR structure revealed a novel fold comprising a four strand antiparallel β-sheet and two helical turns stabilized by a complex disulfide bond network that creates an embedded ring around one of the strands. The resulting structure, which we have termed the Tyr-lock peptide family, is stabilized by a tyrosine residue locked into three-dimensional space. Recifin A inhibited the cleavage of phosphodiester bonds by TDPl in a FRET assay with an IC_(50) of 190 nM. Enzyme kinetics studies revealed that recifin A can specifically modulate the enzymatic activity of full-length TDPl while not affecting the activity of a truncated catalytic domain of TDPl lacking the N-terminal regulatory domain (Δ 1-147), suggesting an allosteric binding site for recifin A on the regulatory domain of TDPl. Recifin A represents both the first of a unique structural class of knotted disulnde-rich peptides and defines a previously unseen mechanism of TDPl inhibition that could be productively exploited for potential anticancer applications.
机译:酪氨酸-DNA磷酸二酯酶1(TDP1)是用于致癌细胞对FDA批准的拓扑异构酶抑制剂Topotecan和Irinotecan致敏的分子靶标。天然产物提取物的高通量筛选和TDPL活性抑制剂的份额文库导致从海绵轴南菌SP发现一类新一类打结的环状肽。源提取物的生物测定引导的分馏导致了活性成分的分离,该活性成分被确定为富含乳蛋白A的前所未有的42-残基半胱氨酸的肽。天然NMR结构揭示了一种新的折叠,包括四条链反平行β-片材的新折叠并且由复杂的二硫键网络稳定的两个螺旋转弯,该网络在其中一个股线上产生嵌入环。我们称之为Tyr-Lock肽家族的所得结构通过锁定到三维空间的酪氨酸残基稳定。 Recifin A通过TDPL在FRET测定中抑制磷酸二酯键的切割,IC_(50)为190nm。酶动力学研究表明,Recifin A可以特异性地调节全长TDP1的酶活性,同时不会影响缺乏N-末端调节结构域的TDP1的截短催化结构域的活性(δ1-147),表明颠覆性粘合位点在TDP1的监管领域恢复官方。 Recifin A代表着一种独特的结构类富含富含富含肽的肽的第一结构,并定义了可以促进潜在抗癌应用的先前未经TDP1抑制机制。

著录项

  • 来源
    《Journal of the American Chemical Society》 |2020年第50期|21178-21188|共11页
  • 作者单位

    Basic Science Program Leidos Biomedical Research Inc. Frederick National Laboratory for Cancer Research Frederick Maryland 21702 United States Molecular Targets Program Center for Cancer Research NCI-Frederick NIH Frederick Maryland 21702 United States;

    Molecular Targets Program Center for Cancer Research NCI-Frederick NIH Frederick Maryland 21702 United States;

    Developmental Therapeutics Branch Laboratory of Molecular Pharmacology NCI NIH Bethesda Maryland 20892 United States;

    Molecular Targets Program Center for Cancer Research NCI-Frederick NIH Frederick Maryland 21702 United States;

    Molecular Targets Program Center for Cancer Research NCI-Frederick NIH Frederick Maryland 21702 United States;

    Developmental Therapeutics Branch Laboratory of Molecular Pharmacology NCI NIH Bethesda Maryland 20892 United States;

    Molecular Targets Program Center for Cancer Research NCI-Frederick NIH Frederick Maryland 21702 United States;

    Molecular Targets Program Center for Cancer Research NCI-Frederick NIH Frederick Maryland 21702 United States;

    Chemical Biology Laboratory Center for Cancer Research NCI-Frederick NIH Frederick Maryland 21702 United States;

    Molecular Targets Program Center for Cancer Research NCI-Frederick NIH Frederick Maryland 21702 United States;

    Developmental Therapeutics Branch Laboratory of Molecular Pharmacology NCI NIH Bethesda Maryland 20892 United States;

    School of Biomedical Sciences The University of Queensland Brisbane QLD 4072 Australia;

    Institute for Molecular Bioscience The University of Queensland Brisbane QLD 4072 Australia Chemical Biology Laboratory Center for Cancer Research NCI-Frederick NIH Frederick Maryland 21702 United States;

    Molecular Targets Program Center for Cancer Research NCI-Frederick NIH Frederick Maryland 21702 United States Natural Products Branch Developmental Therapeutics Program Division of Cancer Treatment and Diagnosis National Cancer Institute Frederick Maryland 21702 United States;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号